

# Larazotide acetate

Catalog No: tcsc8047



## Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg



## Specifications

**CAS No:**

881851-50-9

**Formula:**

$C_{34}H_{59}N_9O_{12}$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 3.2 mg/mL (4.07 mM; Need ultrasonic and warming); H<sub>2</sub>O : ≥ 20 mg/mL (25.45 mM)

**Observed Molecular Weight:**

785.89

## Product Description


Larazotide acetate is a synthetic peptide that functions as a tight junction regulator and reverses leaky junctions to their normally

closed state.

IC50 & Target: Paracellular permeability<sup>[1]</sup>

***In Vitro:*** Larazotide acetate inhibits the redistribution and rearrangement of zonula occludens-1 (ZO-1) and actin caused by AT-1002 and gliadin fragments in Caco-2 and IEC6 cells. Larazotide acetate inhibits the AT-1002-induced TEER reduction and TJ opening in Caco-2 cells. Larazotide acetate inhibits the translocation of a gliadin 13-mer peptide, which has been implicated in celiac disease, across Caco-2 cell monolayers. Further, apically applied Larazotide acetate inhibits the increase in TJ permeability elicited by basolaterally applied cytokines<sup>[1]</sup>.

***In Vivo:*** When tested *in vivo* in gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice, larazotide acetate inhibits gliadin-induced macrophage accumulation in the intestine and preserved normal tight junction structure<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!